• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

影响肾细胞癌脊柱转移患者手术治疗后生存和预后的因素。

Factors affecting survival and prognosis in surgically treated patients with spinal metastases arising from renal cell carcinoma.

机构信息

Graduate School, Tianjin Medical University, No. 22, Qi-xiang-tai Road, He-ping District, Tianjin, 300070, China.

Department of Orthopedics, Tianjin Hospital, Tianjin University, No.406, Jie-fang South Road, Hexi District, Tianjin, 300210, China.

出版信息

BMC Urol. 2023 Jul 13;23(1):118. doi: 10.1186/s12894-023-01294-7.

DOI:10.1186/s12894-023-01294-7
PMID:37443069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10347819/
Abstract

BACKGROUND

The objective of this study was to explore the prognostic factors for renal cell carcinoma (RCC) patients with spinal metastasis who underwent surgical treatment in our hospital.

METHODS

We retrospectively analyzed the clinical data and survival status of 49 patients with spinal metastases arising from RCC. All patients with spinal metastases underwent surgical treatment. We analyzed a range of factors that may affect the prognosis of patients with RCC. Using Kaplan-Meier method to perform univariate analysis of the factors that might affect spine metastasis free survival (SMFS)and survival after spinal metastasis (OS) respectively. Establish Cox proportional hazards model to extract independent prognostic factors for SMFS and OS.

RESULTS

The mean time of SMFS was 27 months (median 8, range 0-180 months). The mean time of OS was 12.04 months (median 9, range 2-36 months). RCC with visceral metastasis (p = 0.001,HR 11.245,95%CI 2.824-44.776) and AJCC RCC Stage (p = 0.040,HR 2.809,95%CI 1.046-7.543) can significantly affect SMFS. Furthermore, WHO/ISUP Grade (p < 0.001, HR 2.787,95%CI 1.595-4.870), ECOG Score (p = 0.019, HR 0.305,95%CI 0.113-0.825) and multiple spinal metastases (p < 0.001, HR 0.077,95%CI 0.019-0.319) have significant effects on OS.

CONCLUSIONS

RCC with visceral metastasis and AJCC RCC Stage were independent prognostic factors for SMFS. WHO/ISUP Grade, ECOG Scores and multiple spinal metastases were independent prognostic factors for OS.

摘要

背景

本研究旨在探讨我院行手术治疗的肾细胞癌(RCC)脊柱转移患者的预后因素。

方法

回顾性分析 49 例 RCC 脊柱转移患者的临床资料和生存状况。所有脊柱转移患者均行手术治疗。分析可能影响 RCC 患者预后的多种因素。采用 Kaplan-Meier 法分别对可能影响脊柱转移无进展生存(SMFS)和脊柱转移后生存(OS)的因素进行单因素分析。建立 Cox 比例风险模型提取 SMFS 和 OS 的独立预后因素。

结果

SMFS 的平均时间为 27 个月(中位数 8 个月,范围 0-180 个月)。OS 的平均时间为 12.04 个月(中位数 9 个月,范围 2-36 个月)。RCC 合并内脏转移(p=0.001,HR 11.245,95%CI 2.824-44.776)和 AJCC RCC 分期(p=0.040,HR 2.809,95%CI 1.046-7.543)可显著影响 SMFS。此外,WHO/ISUP 分级(p<0.001,HR 2.787,95%CI 1.595-4.870)、ECOG 评分(p=0.019,HR 0.305,95%CI 0.113-0.825)和多发脊柱转移(p<0.001,HR 0.077,95%CI 0.019-0.319)对 OS 有显著影响。

结论

RCC 合并内脏转移和 AJCC RCC 分期是 SMFS 的独立预后因素。WHO/ISUP 分级、ECOG 评分和多发脊柱转移是 OS 的独立预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f028/10347819/9c6b8929f261/12894_2023_1294_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f028/10347819/538d03cc7b47/12894_2023_1294_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f028/10347819/9c6b8929f261/12894_2023_1294_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f028/10347819/538d03cc7b47/12894_2023_1294_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f028/10347819/9c6b8929f261/12894_2023_1294_Fig2_HTML.jpg

相似文献

1
Factors affecting survival and prognosis in surgically treated patients with spinal metastases arising from renal cell carcinoma.影响肾细胞癌脊柱转移患者手术治疗后生存和预后的因素。
BMC Urol. 2023 Jul 13;23(1):118. doi: 10.1186/s12894-023-01294-7.
2
Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.影响 37 例连续行初发立体定向放射外科治疗肾细胞癌椎体转移连续部位患者生存的因素。
J Neurosurg Spine. 2015 Jan;22(1):52-9. doi: 10.3171/2014.9.SPINE1482.
3
Factors affecting survival in 267 consecutive patients undergoing surgery for spinal metastasis from renal cell carcinoma.影响 267 例肾细胞癌脊柱转移患者手术预后的因素分析。
J Neurosurg Spine. 2014 Jan;20(1):108-16. doi: 10.3171/2013.9.SPINE13158. Epub 2013 Nov 8.
4
Factors associated with improved survival following surgery for renal cell carcinoma spinal metastases.肾细胞癌脊柱转移瘤手术后生存改善相关因素。
Neurosurg Focus. 2016 Aug;41(2):E13. doi: 10.3171/2016.5.FOCUS16145.
5
Outcomes of patients with spinal metastases from renal cell carcinoma treated with conventionally-fractionated external beam radiation therapy.接受常规分割外照射放疗的肾细胞癌脊柱转移患者的治疗结果。
Medicine (Baltimore). 2020 Apr;99(16):e19838. doi: 10.1097/MD.0000000000019838.
6
[Clinical characteristics and prognosis of renal cell carcinoma patients with bone metastases].肾细胞癌骨转移患者的临床特征与预后
Zhonghua Yi Xue Za Zhi. 2020 Apr 14;100(14):1068-1071. doi: 10.3760/cma.j.cn112137-20190809-01784.
7
Outcomes and prognostic factors for surgically treated patients with breast cancer spine metastases.接受手术治疗的乳腺癌脊柱转移患者的结局及预后因素
J Bone Oncol. 2018 Apr 13;12:38-43. doi: 10.1016/j.jbo.2018.03.003. eCollection 2018 Sep.
8
The treatment of vertebral metastases from renal cell carcinoma: a retrospective study.肾细胞癌椎体转移瘤的治疗:一项回顾性研究。
Minerva Urol Nefrol. 2017 Apr;69(2):166-172. doi: 10.23736/S0393-2249.16.02809-5. Epub 2016 Oct 21.
9
Survival pattern of metastatic renal cell carcinoma patients according to WHO/ISUP grade: a long-term multi-institutional study.根据世界卫生组织/国际泌尿病理学会分级的转移性肾细胞癌患者的生存模式:一项长期的多机构研究。
Sci Rep. 2024 Feb 27;14(1):4740. doi: 10.1038/s41598-024-54052-6.
10
Prognosis of renal cell carcinoma with bone metastases: Experience from a large cancer centre.骨转移肾细胞癌的预后:来自一个大型癌症中心的经验。
Eur J Cancer. 2019 Jan;107:79-85. doi: 10.1016/j.ejca.2018.10.023. Epub 2018 Dec 11.

本文引用的文献

1
Separation Surgery in the Treatment of Spinal Metastasis.脊柱转移瘤的分离手术治疗。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221107208. doi: 10.1177/15330338221107208.
2
Hybrid Therapy (Surgery and Radiosurgery) for the Treatment of Renal Cell Carcinoma Spinal Metastases.手术联合放射外科治疗肾细胞癌脊柱转移瘤。
Neurosurgery. 2022 Feb 1;90(2):199-206. doi: 10.1227/NEU.0000000000001780.
3
Phase 2 Clinical Trial of Separation Surgery Followed by Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord Compression.
分离手术联合立体定向体部放射治疗转移性硬膜外脊髓压迫的 2 期临床试验。
Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):106-113. doi: 10.1016/j.ijrobp.2021.07.1690. Epub 2021 Oct 26.
4
Prognostic significance of the combination of preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) in patients with renal cell carcinoma after nephrectomy.肾切除术后肾癌患者术前血红蛋白与白蛋白水平及淋巴细胞和血小板计数组合(HALP)的预后意义
BMC Urol. 2018 Mar 15;18(1):20. doi: 10.1186/s12894-018-0333-8.
5
Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.透明细胞肾细胞癌:世界卫生组织/国际泌尿病理学会分级的验证。
Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311. Epub 2017 Oct 2.
6
Preoperative combined hemoglobin, albumin, lymphocyte and platelet levels predict survival in patients with locally advanced colorectal cancer.术前血红蛋白、白蛋白、淋巴细胞和血小板联合水平可预测局部晚期结直肠癌患者的生存情况。
Oncotarget. 2016 Nov 1;7(44):72076-72083. doi: 10.18632/oncotarget.12271.
7
Spinal metastasectomy of renal cell carcinoma: A 16-year single center experience with a minimum 3-year follow-up.肾细胞癌脊柱转移瘤切除术:一项单中心16年经验,至少随访3年。
J Surg Oncol. 2016 Apr;113(5):587-92. doi: 10.1002/jso.24186. Epub 2016 Feb 5.
8
Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study.术前血红蛋白、白蛋白、淋巴细胞和血小板联合检测对胃癌患者的预后意义:一项回顾性队列研究
Oncotarget. 2015 Dec 1;6(38):41370-82. doi: 10.18632/oncotarget.5629.
9
Renal cell carcinoma.肾细胞癌
BMJ. 2014 Nov 10;349:g4797. doi: 10.1136/bmj.g4797.
10
Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.通过 RNA 测序鉴定 TFE3 蛋白表达的肾细胞癌中的分子肿瘤标志物。
Neoplasia. 2013 Nov;15(11):1231-40. doi: 10.1593/neo.131544.